AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04702919 — intervention group
Intervention type: OTHER
Intervention: Registration
Description: Synchronized recording of BTP in ultrasound, brain activity by EEG, heart rate and blood pressure.
Study NCT04702919 — intervention group
Intervention type: OTHER
Intervention: Auditive oddball task
Description: Presentation of an auditory sequence, comprising 'Standard' (probability of occurrence: p = 0.90) and 'Deviants' (p = 0.10, targets) sounds via loudspeakers.
Study NCT05287451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RIsk-Reducing Salpingectomy (RRS)
Description: complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
Study NCT05287451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Risk-Reducing Oophorectomy-RRO
Description: complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
Study NCT04780919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-6000 FSWT
Description: Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300.
Study NCT04780919 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL-6000 FSWT with sham applicator
Description: Intensity 0,12 mJ/mm2, frequency 10 Hz, total number of shocks 1300 - applied with modified applicator which does not allow wave transmission.
Study NCT05256407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention, digital support
Description: Internet based support of parents in child health care. Various options and choices includes parental education, digital meetings with child health nurse and peer groups
Study NCT05182151 — intervention group
Intervention type: DRUG
Intervention: Istradefylline 40 mg
Description: adenosine A2A receptor antagonist
Study NCT04865068 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography measures on SSA participants
Description: Upon SSA Subject is admitted to the hospital for an echocardiography,~* Information about this study process,~* Participants will receive an information note ;~* Administration of a medical history questionnaire, collection of cardiovascular risk factors, weight toe (all of which are routinely collected before an echocardiographic examination is performed);~* Performing and recording the echocardiographic examination according to routine protocol~* delivery of the results according to the usual management;~* deferred analysis of the recordings on workstation with classification of the data (normal-pathological) according to the different standards
Study NCT04942925 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses for daily disposable wear
Study NCT04942925 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Kalifilcon A contact lenses
Description: Commercially available silicone hydrogel contact lenses for daily disposable wear
Study NCT04907760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized care program
Description: It includes the participant follow-up by a nurse during 5 years with a contact every 4 months for the first year, then after every 6 months
Study NCT06108895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ilio-inguinal/ilio-hypogastric nerve block (IINB)
Description: Ultrasound-guided IINBs will be performed by scanning the anterior abdominal wall superior and medial to the anterior superior iliac spine in a line between the anterior superior iliac spine and umbilicus using a linear probe (4-12hertz). Ilioinguinal and iliohypogastric nerves will be identified in the plane between internal oblique muscle and transversus abdominis muscle. After negative aspiration of blood, 20 ml plain bupivacaine 0.25% plus 4mg dexamesathone will be injected. The same technique will be performed in the other side.
Study NCT06108895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine
Description: 200 mcg morphine intrathecally with bupivacaine
Study NCT05677555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.
Study NCT05677555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
Study NCT06267196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The use of a stress ball
Description: The effect of the stress ball used during spinal anesthesia on pain and anxiety
Study NCT05424653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve System
Description: Procedure: Transcatheter Aortic Valve Replacement
Study NCT04314856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FTC-146
Description: 18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.
Study NCT03976973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelain
Description: Intratumoural injections of Bromelain 600ug/ml (maximum dose 90mg daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Acetylcysteine in 0.9% sodium chloride (normal saline).
Study NCT03976973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Intratumoural injections of Acetylcysteine 20mg/ml (maximum dose 3g daily diluted in 150ml 0.9% NaCl) via a radiologically placed drain in combination with Bromelain.
Study NCT03976973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interventional radiology insertion of drain
Description: Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour, then a pigtail drain (10Frg) will be secured into the tumour by an experienced, interventional radiologist, under standard procedures. This drain is utilised as access to the tumour for injections of the investigational drug product BromAc, and subsequent aspirations.
Study NCT05711290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oxygen Nanobubble
Description: This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)
Study NCT05711290 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen Nanobubble
Description: This intervention consists of oxygenated nanobubbles made from lecithin with natural flavourings (liquorice, glycerol and citric acid)
Study NCT05711290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).
Study NCT05711290 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo does not contain nanobubbles, and is made from natural flavourings (liquorice, glycerol and citric acid).
Study NCT01344928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT exercise intervention
Study NCT01344928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise intervention
Study NCT05456672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meals and food baskets
Description: Interventional dietary study using standardized test meals and personalized food baskets to investigate the impact of food combination on the glycemic response. The study period is organized as follows:~(Day 1: Continuous blood glucose monitoring system (CGM) activation) Days 2 and 3: Two standardized daily menus (breakfast, lunch, afternoon snack and dinner) provided on a randomized crossover basis.~Days 4 to 7: four standardized test meals, participants will be asked to substitute one meal each day (lunch or dinner) for a test meal according to a pre-defined randomization plan.~Days 8 to 10: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items.~Days 11 to 13: Participants will be asked to prepare all meals using a food basket containing a mix of standardized and personal preference items and following dietary recommendations developed by the study staff.~(Day 14: CGM sensor removed)
Study NCT05026398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Description: Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
Study NCT05026398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution
Study NCT05374538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIC-1911
Description: VIC-1911 tablets for oral administration
Study NCT05395442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Training on web-based diabetic foot care based on the Health Belief Model
Description: Training on web-based diabetic foot care based on the Health Belief Model will be implemented.Four materials will be used in the research, namely the Introductory Information Form, the Foot Care Behavior Scale, the Diabetic Foot Care Self-Efficacy Scale.
Study NCT05374538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Sotorasib tablets for oral administration
Study NCT06372561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate (dressing material)
Description: MTA (Angulus Industrial de productus Odontologists S/a, Brazil) that applied on dental pulp for tissue regeneration
Study NCT06372561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (dressing material)
Description: MTA (Angulus Industrial de productus Odontologists S/a, Brazil) that applied on dental pulp for tissue regeneration
Study NCT06372561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin (dressing material)
Description: melatonin powder 250mg (sigma, Aldrich)- white powder mixing with saline and applied on dental pulp
Study NCT04834596 — intervention group
Intervention type: OTHER
Intervention: retrospectives analysis on hepatic scanner
Description: hepatic scanner will be analysed by two radiologist and by the software
Study NCT04767451 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound assessment
Description: Lead (Pb), Cadmium (Cd), Gadolinium (Gd), Arsenic (As), Mercury (Hg), Cobalt (Co), Vanadium (V), Titanium (Ti), Sulfur (S), Chromium (Cr), Silver (Ag), Molybdenum (Mo), Boron (B), Lithium (Li), and Nickel (Ni) measurements
Study NCT04194632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary right ventricular pacing
Description: As described previously. Patients will undergo temporary pacing at the site of latest endocardial activation with measurement of hemodynamic effects.
Study NCT06085144 — intervention group
Intervention type: DRUG
Intervention: Galcanezumab
Description: Receiving either 120mg or 300mg injections.
Study NCT04200729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigation with PVI
Description: The intervention will be irrigation with PVI, diluted to a concentration of 1% (containing 0.1% active iodine). After removal of the appendix from the patient's abdomen and attainment of hemostasis,10 mL/kg of 1% PVI solution will be used to irrigate the pelvis and right upper and lower quadrants. The solution will be left to dwell for 1 minute and then suctioned.
Study NCT05759910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brainphyt high dose
Description: Participants will take BrainPhyt capsules during 3 months
Study NCT05759910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebo capsules during 3 months
Study NCT04200729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control will be usual care, which is expected to vary between institutions. The only stipulation for usual care will be that surgeons do not change their usual practice during the baseline period. Some surgeons utilize intra-abdominal irrigation while others use only local irrigation. Intraabdominal irrigation is defined as intraoperative instillation of a large volume (> 200 mL) of irrigation solution into all 4 quadrants of the abdomen. Local irrigation is defined as instillation of a small volume of liquid, typically \<50 mL, in the operative field. Intra-abdominal irrigation is utilized with the intention of preventing IAAs while local irrigation is often used to confirm hemostasis or assist with suctioning thick purulent fluid.
Study NCT05814835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-4 mCi 68Ga/64Cu-FAPI-XT117
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.
Study NCT05814835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-6 mCi 68Ga/64Cu-FAPI-XT117
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.
Study NCT05814835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-8 mCi 68Ga/64Cu-FAPI-XT117
Description: 68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.
Study NCT05998863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EffCaMgCit
Description: Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
Study NCT05998863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate.
Study NCT05107375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent influenza virus lysis vaccine
Description: Influenza virus lysis vaccine, one dose at a time, each dose 0.5mL, containing each influenza virus strain hemagglutinin 15μg.
Study NCT05107375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant new coronavirus vaccine (CHO cell) group
Description: One dose of recombinant Novel Coronavirus vaccine (CHO cells) was administered at 0.5mL each dose, containing 25μg nCP-RBD protein.
Study NCT05743972 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound-guided core biopsy
Description: Core biopsy was used to collect samples for pancreatic diseases under contrast-enhanced ultrasound-guided.
Study NCT05743972 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ultrasound-guided core biopsy
Description: Core biopsy was used to collect samples for pancreatic diseases under conventional ultrasound-guided.
Study NCT04796857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody
Description: Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.
Study NCT04796857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Phase I: dose escalation phase. Patients will oral dosage as 10mg, 20mg, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral lenalidomide as RP2D up to 6 cycles during induction phase
Study NCT06518226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated MRgRT in 2 fractions
Description: 2x12 Gy with boost to GTV up to 13.5 Gy
Study NCT06518226 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care: MRgRT in 5 fractions
Description: 5x7.25 Gy
Study NCT05853900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReMMi-D Digital Therapeutic
Description: Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents.
Study NCT05695313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnLife®
Description: It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. The OnLife supplement will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily
Study NCT05695313 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. Placebo will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily
Study NCT04781062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood and urine molecular analysis (Timing 0)
Description: peripheral blood and urine sample collection
Study NCT04781062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and urine molecular analysis (Timing 0)
Description: peripheral blood and urine sample collection
Study NCT04781062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and urine molecular analysis (Timing 1)
Description: peripheral blood and urine sample collection
Study NCT05257616 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traction Mobilization technique
Description: Traction Mobilization was given by Researcher at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again. Participant sits comfortably or leans against a chair backrest. Palms of the hands are placed on the mastoid processes of the patient's skull while pressing the elbows in a caudal direction. It was held for 5 seconds then relaxed.
Study NCT05257616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traction Mobilization technique with SNAGS
Description: Traction Mobilization with SNAGS were given at the cervical spine followed by a one minute interval before post vitals were taken, that marked the end of the first session. Three similar sessions succeeded the first, each at an interval of 2 days for 2 weeks between the first and second session; third and fourth session respectively. At the end of the fourth session, cervical ranges and pain intensity were noted again The position of the therapist is behind him or her, medial border of therapist's right thumb is used to contact the spinous process of C6 vertebrae i.e. level above the suspected painful or hypo mobile region. Therapist's left thumb reinforces his/her (right) contact thumb. Therapist fingers are gently placed along the patient's mandible or thorax. Following the treatment plane towards the eye, lift comes from the mobilizing thumb not the contact thumb. While the glide is maintained, the patient is asked to rotate his/her head towards the side of pain or hypo mobility.
Study NCT05507177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: communication training programme for healthcare providers
Description: the communication training programme is specifically designed to help Dutch primary care healthcare providers facilitate adequately deprescribing cardiometabolic medication in older patients
Study NCT06391671 — intervention group
Intervention type: OTHER
Intervention: Collection of anthropometric data, biological samples (stool, saliva and hair), questionnaires (demographic data, psychological data, medical data)
Description: Saliva and feces are collected at the families home. A questionnaire is filled in by the participant (psychological) and parents (demographical and medical info). Upon consultation we are collecting anthropometric data (date of birth, length, weight, abdominal circumference, Tanner pubertal stage, etc.)
Study NCT05716880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketosteril
Description: Daily dose = 1 tabl / 5 kg of ideal body weight
Study NCT05716880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Protein Diet (MPD)
Description: MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria
Study NCT05716880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium Protein Diet (MPD)
Description: MPD: daily protein intake of 0.8-1.0 g/kg of ideal body weight + up to 5 g based on daily proteinuria
Study NCT06302907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buffered Local anaesthesia
Description: A buffered 2% lidocaine with 1:80000 epinephrine and sodium bicarbonate 8.4% was used for one site
Study NCT06302907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unbuffered Local anaesthesia
Description: an unbuffered 2% lidocaine with 1: 80000 epinephrine for the other site at the same appointment.